Pipeline

Last Updated Date: February 8, 2024

We have the strongest and most diversified pipeline in our history and are on track to achieve our ambition, set in 2019, of delivering 10+ transformative therapies by 2030.

Total programs

From long-acting HIV combinations to some of the most promising targets in cancer treatment, we’re discovering, evaluating and advancing investigational compounds that have the potential to transform care for life-threatening diseases. Through pioneering science and innovative partnerships, we’ll continue to expand our research and development programs to take on pressing unmet needs in virology, oncology and inflammation.

Learn more about our ambitions for each therapeutic area

Filter by:

Therapeautic Area:

Virology
Oncology
Inflammation
Trial Phase
Please select at least one filter to refine your search.

Search within results

There are no results for this query. Please adjust your search and try again.

Virology

Emerging Viruses

  • Obeldesivir (OAKTREE)

    COVID-19

    Phase 3

HIV

  • Lenacapavir (PURPOSE 1 & 2)

    HIV pre-exposure prophylaxis (PrEP)

    Phase 3
  • Lenacapavir/bictegravir oral combination (ARTISTRY-1)

    HIV treatment for virologically suppressed treatment-experienced people living with HIV

    Phase 3
  • Lenacapavir

    Long-acting HIV treatment for virologically suppressed people living with HIV

    Phase 2

Notes

Phase 2 study being conducted in treatment naïve patients to support virologically suppressed indication.

  • Lenacapavir/islatravir oral combination

    Long-acting HIV treatment for virologically suppressed people living with HIV

    Phase 2

Notes

Subject to Gilead and Merck co-development and co-commercialization agreement.

  • Lenacapavir + teropavimab + zinlirvimab

    Long-acting HIV treatment for virologically suppressed people living with HIV

    Phase 2

Notes

Teropavimab and zinlirvimab are broadly neutralizing antibodies (bNAB).

  • Teropavimab + zinlirvimab

    HIV cure

    Phase 2

Notes

Non-Gilead sponsored trial(s) ongoing.

Teropavimab and zinlirvimab are broadly neutralizing antibodies (bNAB).

  • Vesatolimod

    HIV cure

    Phase 2
  • HIV bispecific T-cell engager (GS-8588)

    HIV cure

    Phase 1
  • HIV long-acting injectable INSTI (GS-6212)

    Long-acting HIV treatment

    Phase 1

Notes

INSTI – Integrase strand transfer inhibitor

  • HIV long-acting oral INSTI (GS-1720)

    Long-acting HIV treatment

    Phase 1

Notes

INSTI – Integrase strand transfer inhibitor

  • HIV long-acting oral capsid inhibitor (GS-4182)

    Long-acting HIV treatment

    Phase 1
  • HIV long-acting injectable NNRTI (GS-1614)

    Long active HIV treatment

    Phase 1

Notes

Subject to Gilead and Merck co-development and co-commercialization agreement. 

NNRTI - non-nucleoside reverse transcriptase inhibitor

HBV

  • Selgantolimod

    HBV cure

    Phase 2
  • HBV therapeutic vaccine (GS-2829 + GS-6779)

    HBV cure

    Phase 1

HDV

  • Hepcludex® (MYR301)

    HDV

    Phase 3

Notes

Full Marketing Authorisation by the European Medicines Agency (EMA) for the treatment of adults with chronic HDV and compensated liver disease.

Breakthrough Therapy and PRIME designations.

Biologics License Application resubmission to FDA pending.

  • Bulevirtide (MYR204)

    HDV Finite

    Phase 2

Potential Opt-in Programs

  • Gritstone

    HIV Cure

    1 CLINICAL STAGE PROGRAMS

Oncology

Breast

  • Sacituzumab govitecan-hziy (ASCENT-03)

    1L metastatic triple-negative breast cancer (PD-L1-)

    Phase 3

Notes

PD-L1 – programmed death-ligand 1

  • Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-04)

    1L metastatic triple-negative breast cancer (PD-L1+)

    Phase 3

Notes

In collaboration with Merck.

PD-L1 – programmed death-ligand 1

  • Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-05)

    Adjuvant triple-negative breast cancer

    Phase 3
  • Sacituzumab govitecan-hziy (ASCENT-07)

    HR+/HER2- chemo-naïve metastatic breast cancer

    Phase 3

Notes

HR+/HER2- - Hormone receptor positive, human epidermal growth factor receptor 2 negative

  • Magrolimab + chemotherapy/sacituzumab govitecan-hziy combinations (ELEVATE TNBC)

    Metastatic triple-negative breast cancer

    Phase 2

Lung and Thoracic

  • Sacituzumab govitecan-hziy (EVOKE-01)

    2-3L metastatic non-small cell lung cancer

    Phase 3
  • Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-03)

    1L metastatic non-small cell lung cancer (PD-L1+, TPS>50%)

    Phase 3

Notes

In collaboration with Merck.

PD-L1 – Programmed death-ligand 1

TPS – tumor proportion scale

  • Domvanalimab + zimberelimab + chemotherapy (STAR-121)

    1L metastatic non-small cell lung cancer

    Phase 3

Notes

In collaboration with Arcus Biosciences.

  • Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-02)

    1L metastatic non-small cell lung cancer

    Phase 2

Notes

In collaboration with Merck.

TPS – tumor proportion scale

  • Domvanalimab + zimberelimab + etrumadenant (ARC-7)

    Metastatic non-small cell lung cancer

    Phase 2

Notes

In collaboration with Arcus Biosciences.

  • Lung cancer platform (VELOCITY-Lung, EDGE-Lung)

    Non-small cell lung cancer

    Phase 2

Notes

VELOCITY-Lung includes combinations of domvanalimab, etrumadenant, zimberelimab, and sacituzumab govitecan-hziy.

EDGE-Lung, in collaboration with Arcus Biosciences, includes immunotherapy-based combinations of quemliclustat, domvanalimab, and zimberelimab

EDGE-Lung includes immunotherapy-based combinations of quemliclustat, domvanalimab, and zimberelimab.

  • Magrolimab + chemotherapy/IO combinations (ELEVATE HNSCC)

    Head and neck squamous cell carcinoma

    Phase 2

Notes

IO - Immuno-oncology

Genitourinary

  • Trodelvy® (TROPiCS-04)

    2L metastatic urothelial carcinoma

    Phase 3

Notes

The FDA granted accelerated approval for Trodelvy®️ in 2L mUC Apr 2021 based on TROPHY U-01 Phase 1b trial.

  • Sacituzumab govitecan-hziy + combinations (TROPHY U-01)

    1L metastatic urothelial carcinoma

    Phase 2

Gastrointestinal

  • Domvanalimab + zimberelimab + chemotherapy (STAR-221)

    1L upper Gastrointestinal cancer

    Phase 3

Notes

In collaboration with Arcus Biosciences.

  • Etrumadenant + zimberelimab combinations (ARC-9)

    Metastatic colorectal cancer

    Phase 2

Notes

In collaboration with Arcus Biosciences.

  • Quemliclustat + zimberelimab (ARC-8)

    Metastatic pancreatic ductal adenocarcinoma

    Phase 2

Notes

In collaboration with Arcus Biosciences.

  • Magrolimab combinations (ELEVATE CRC)

    Metastatic colorectal cancer

    Phase 2

Other Solid Tumors

  • Sacituzumab govitecan-hziy (TROPiCS-03)

    Basket (Solid tumors)

    Phase 2
  • Magrolimab + chemotherapy (ELEVATE Lung & Urothelial Carcinoma)

    Solid tumors

    Phase 2

Hematological Malignancies

  • Magrolimab combinations

    Diffuse large B-cell lymphoma

    Phase 2

Advanced Cancers

  • CCR8 (GS-1811)

    Advanced cancers

    Phase 1
  • MCL1 inhibitor (GS-9716)

    Advanced cancers

    Phase 1
  • IL-2 Variant (GS-4528)

    Advanced cancers

    Phase 1

Notes

IL – Interleukin

  • DGKα Inh (GS-9911)

    Advanced cancers

    Phase 1

Cell Therapy

  • Axicabtagene ciloleucel (ZUMA-22)

    2L+ high-risk follicular lymphoma

    Phase 3
  • Axicabtagene ciloleucel (ZUMA-23)

    1L high-risk large B-cell lymphoma

    Phase 3
  • Axicabtagene ciloleucel (ZUMA-24)

    2L large B-cell lymphoma outpatient

    Phase 2
  • Brexucabtagene autoleucel (ZUMA-4)

    Pediatric acute lymphocytic leukemia/ non-Hodgkin lymphoma

    Phase 2
  • Brexucabtagene autoleucel (ZUMA-25)

    Basket (rare B-cell malignancies)

    Phase 2
  • Anitocabtagene autoleucel (iMMagine-1)

    Relapsed/refractory multiple myeloma

    Phase 2

Notes

Global strategic collaboration to co-develop and co-commercialize with Arcellx. 

  • CLL-1 (KITE-222)

    Relapsed/refractory acute myeloid leukemia

    Phase 1
  • CD19/20 bicistronic (KITE-363)

    Relapsed/refractory diffuse large B-cell lymphoma

    Phase 1

Notes

CD 19 and 20 are B-lymphocyte antigens. CD – cluster of differentiation

Potential Opt-in Programs

  • Agenus

    Advanced cancers

    1 CLINICAL STAGE PROGRAMS
  • Arcus

    Advanced cancers

    3 CLINICAL STAGE PROGRAMS
  • MacroGenics

    Advanced cancers

    1 CLINICAL STAGE PROGRAMS
  • Galapagos

    Advanced cancers

    3 CLINICAL STAGE PROGRAMS

Inflammation

Inflammatory Diseases

  • Edecesertib (COSMIC)

    Lupus

    Phase 2
  • Tilpisertib fosmecarbil (PALEKONA)

    Inflammatory bowel disease

    Phase 2

Notes

Phase 2 FPI achieved

FPI - first patient in (patient screening + consent)

  • α4β7 inhibitor (GS-1427)

    Inflammatory bowel disease

    Phase 1
  • BTLA agonist (GS-0272)

    Inflammatory diseases

    Phase 1

Notes

BTLA - B- and T-lymphocyte attenuator

Fibrotic Diseases

  • Cilofexor / firsocostat / semaglutide combination

    Nonalcoholic steatohepatitis

    Phase 2

Notes

Clinical collaboration with Novo Nordisk.

Potential Opt-in Programs

  • Galapagos

    Inflammatory diseases

    1 CLINICAL STAGE PROGRAMS